Svendsen U G, Frølund L, Heinig J H, Madsen F, Nielsen N H, Weeke B
Lungemedicinsk/allergologisk afdeling, Københavns Amts Sygehus i Gentofte.
Ugeskr Laeger. 1993 Jul 12;155(28):2197-202.
The effects of high-dose inhaled budesonide (800 micrograms twice daily) and those of inhaled beclomethasone dipropionate (750 micrograms twice daily) were compared with respect to lung function, symptoms, bronchial reactivity and adrenocortical function in a doubleblind, double-dummy cross-over study. The subjects were 40 adult patients suffering from either allergic or non-allergic asthma. The asthma was categorized as moderate to severe, and the asthma was insufficiently controlled on inhalational steroids given in doses of 300 to 500 micrograms daily. After a two week "run-in" period the patients were randomized to six weeks treatment with either budesonide or beclomethasone dipropionate, followed by six weeks treatment with the opposite drug. Both inhaled budesonide and inhaled beclomethasone dipropionate were able to improve objective measures of lung function and bronchial sensitivity to histamine. Neither drug affected adrenocortical function, and no serious side-effects were noted during the trial. It is concluded that budesonide and beclomethasone dipropionate are safe and effective drugs for the treatment of asthma in adults. The substances are equally effective taken microgram for microgram.
在一项双盲、双模拟交叉研究中，比较了高剂量吸入布地奈德（每日两次，每次800微克）和吸入丙酸倍氯米松（每日两次，每次750微克）对肺功能、症状、支气管反应性和肾上腺皮质功能的影响。受试者为40名患有过敏性或非过敏性哮喘的成年患者。哮喘被分类为中度至重度，且每日给予300至500微克吸入性类固醇时哮喘控制不佳。经过两周的“导入期”后，患者被随机分为接受布地奈德或丙酸倍氯米松治疗六周，随后接受相反药物治疗六周。吸入布地奈德和吸入丙酸倍氯米松均能够改善肺功能的客观指标以及支气管对组胺的敏感性。两种药物均未影响肾上腺皮质功能，且试验期间未观察到严重副作用。结论是布地奈德和丙酸倍氯米松是治疗成人哮喘的安全有效药物。两种药物按微克计算效果相当。
